
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is in a strong financial position with $516.5M in cash, cash equivalents and marketable securities, enough to fund operations until 2029. The company's pipeline is focused on three therapeutic areas and its proprietary Native Complex Platform has the potential to unlock the full potential of GPCR therapies. Septerna's lead candidate, SEP-479, has shown a 3-4 day human half-life and Phase 1 data is expected in 2027, which could be a major de-risking event. The company's financial results have been better than expected, and with a strong cash runway and potential positive data in the near future, the analyst has a positive outlook on the company's stock.
Bears say
Septerna is facing significant risks to its stock price target achievement due to delays and setbacks in clinical trials, partnership risks, and potential approval failures for its lead candidates. Additionally, the estimated valuation of $60 per share is based on a conservative assessment of the company's pipeline, and there is a possibility for long-term dilution risk. The company's current phase 1 trial of SEP-479, its lead PTH1R candidate, has shown positive PK data but may not report conclusive results until 2027, with a potential launch in 2031. The bull case for the company's stock price is $70, assuming a 50% probability of success for SEP-479 and potential revenue of $2.3B in 2040.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares